| Unique ID issued by UMIN | UMIN000061654 |
|---|---|
| Receipt number | R000070543 |
| Scientific Title | A study to verify the safety of excessive consumption of the test food: an open-label study |
| Date of disclosure of the study information | 2026/05/22 |
| Last modified on | 2026/05/22 10:55:10 |
A study to verify the safety of excessive consumption of the test food: an open-label study
A study to verify the safety of excessive consumption of the test food: an open-label study
A study to verify the safety of excessive consumption of the test food: an open-label study
A study to verify the safety of excessive consumption of the test food
| Japan |
Healthy Japanese
| Not applicable | Adult |
Others
NO
To conduct a safety verification study for excessive consumption of five times the recommended daily intake of Lactococcus cremoris subsp. cremoris YRC3780.
Safety
Confirmatory
Pragmatic
Not applicable
1. Individuals who experienced adverse events
1. Individuals whose values of urinalysis and peripheral blood test are outside the reference range after intervention despite within the reference range at screening
2. Physical measurements, urinalysis, and peripheral blood test
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Educational,Counseling,Training
| Food |
Duration: Four weeks
Test product: Capsule containing Lactococcus cremoris subsp. cremoris YRC3780 powder
Administration: Take 10 capsules with water without chewing per day.
*If you forget to take the test food, take it as soon as you remember. Daily dose should be taken within the day and not carried over to the next day.
| 18 | years-old | <= |
| Not applicable |
Male and Female
1. Japanese
2. Men or women
3. Adults
4. Healthy individuals
1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction
2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims"
5. Individuals who are taking or using medications (including herbal medicines) or supplements
6. Individuals who are allergic to medicines or foods related to the test product
7. Individuals who are pregnant, lactating, or planning to become pregnant during this study
8. Individuals who are judged as ineligible to participate in this study by the physician
10
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Medical Corporation Seishinkai, Takara Clinic
Director
141-0022
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
t-takara@takara-clinic.com
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
ORTHOMEDICO Inc.
R&D Department
112-0002
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan
03-3818-0610
nao@orthomedico.jp
Yotsuba Milk Products Co., Ltd.
Yotsuba Milk Products Co., Ltd.
Profit organization
The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
IRB@takara-clinic.com
NO
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
| 2026 | Year | 05 | Month | 22 | Day |
Unpublished
Open public recruiting
| 2026 | Year | 05 | Month | 13 | Day |
| 2026 | Year | 05 | Month | 13 | Day |
| 2026 | Year | 05 | Month | 22 | Day |
| 2026 | Year | 09 | Month | 01 | Day |
| 2026 | Year | 05 | Month | 22 | Day |
| 2026 | Year | 05 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070543